Option Care Health (OPCH) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Option Care Health published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Option Care Health reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted diluted EPS, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• On October 5, 2026, Option Care Health agreed to be acquired by an investor group of Clayton, Dubilier & Rice and McKesson for $32.05 a share in cash. Because of the pending deal it held no earnings call and withdrew its previously disclosed financial guidance.
• Option Care Health has one reportable segment, infusion services. The rows above are its disclosed net revenue by category of payer. It reports in thousands of dollars; figures here are converted to millions.

Source: Option Care Health Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Option Care Health splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Option Care Health's Commercial payers revenue was $1.3 billion in Q3 2026, up 3% from $1.3 billion in Q3 2025, 86% of total revenue.
• Option Care Health's Government payers revenue was $194 million in Q3 2026, up 12% from $173 million in Q3 2025, 13% of total revenue.
• Option Care Health's Patients revenue was $15.3 million in Q3 2026, up 51% from $10.1 million in Q3 2025, 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net revenue and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Option Care Health's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

Option Care Health provides home and alternate site infusion services: it dispenses infused drugs and supplies and provides nursing and clinical support, mostly in patients' homes and also in ambulatory infusion suites. Its 2025 Form 10-K describes a national network of 87 full-service pharmacies, 73 of them with ambulatory infusion suites, plus 109 stand-alone ambulatory infusion suites. Net revenue in Q3 2026 was $1,493.5 million, up 4.1%. (Option Care Health Q3 2026 release, Nov 4, 2026; Option Care Health Form 10-K, 2025, Feb 24, 2026)

Option Care Health attributed the growth mainly to its acute portfolio of therapies, which grew at a high-single-digit rate. Its chronic therapies grew at a low-single-digit rate: immunoglobulin and neurology therapies and the rare and orphan portfolio grew, while the chronic inflammatory disease (CID) portfolio declined because of patient attrition and unfavorable therapy mix. (Option Care Health Form 10-Q, Q3 2026, Nov 4, 2026)

Commercial payers accounted for $1,284.1 million of Option Care Health's net revenue in Q3 2026, government payers $194.2 million and patients $15.3 million. About 13% of revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid, against about 12% a year earlier. Its largest payer represented about 14% of revenue in 2025, and no other payer was more than 10%. (Option Care Health Form 10-Q, Q3 2026, Nov 4, 2026; Option Care Health Form 10-K, 2025, Feb 24, 2026)

Gross profit rose 4.4% to $285.0 million, a margin of 19.1% against 19.0%. Option Care Health said growth in higher-margin therapies and operational initiatives were partly offset by therapy mix shifts, and it continues to expect CID-related dynamics to reduce 2026 gross profit by about $55 million. (Option Care Health Form 10-Q, Q3 2026, Nov 4, 2026)

Option Care Health's GAAP diluted EPS was $0.38 in Q3 2026, up 18.8% from $0.32, and adjusted diluted EPS was $0.49, up from $0.45. Adjusted net income of $74.4 million adds back intangible asset amortization ($9.3 million), stock-based incentive compensation ($9.3 million) and restructuring, acquisition, integration and other costs ($4.7 million), less $6.3 million of tax adjustments. Selling, general and administrative expenses rose mainly because of transaction costs for the pending merger. (Option Care Health Q3 2026 release, Nov 4, 2026; Option Care Health Form 10-Q, Q3 2026, Nov 4, 2026)

EPS rose faster than Option Care Health's net income, which grew 10.8% to $57.4 million, because diluted weighted average shares fell to 150,491 thousand from 163,086 thousand. The company bought back 7,880,038 shares for $167.5 million in the first nine months of 2026, at an average of $21.26, and made no repurchases in Q3 2026; the merger agreement bars buybacks without the buyer's consent. The effective tax rate was 27.2%, against 24.9%. (Option Care Health Q3 2026 release, Nov 4, 2026; Option Care Health Form 10-Q, Q3 2026, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Option Care Health has withdrawn its financial guidance. Its Q3 2026 release says that, given the pending acquisition by Clayton, Dubilier & Rice and McKesson, it will not host an earnings call and has withdrawn its previously disclosed guidance. (Option Care Health Q3 2026 release, Nov 4, 2026)

Under the merger agreement signed on October 5, 2026, each Option Care Health share is to be converted into $32.05 in cash. The deal is expected to close in the first half of calendar 2027. Option Care Health would owe a termination fee of about $145.96 million, and the buyer a reverse termination fee of about $291.93 million, if the agreement ends under certain circumstances. (Option Care Health Form 10-Q, Q3 2026, Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover Option Care Health, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Option Care Health's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning OPCH is on is OPCH a buy or a sell?, what analysts expect next is on the OPCH forecast, and what the company does is on the Option Care Health (OPCH) stock page.

Every number on this page can be traced to a document Option Care Health published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.